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Human telomerase, a multicomponent ribonucleoprotein enzyme
that extends chromosome ends with (TTAGGG)n telomeric repeat
sequences, is generally inactive in human normal somatic cells but
active in a variety of human tumour cell lines and primary malig-
nant tissues (Harley et al, 1994; Kim et al, 1994). Activation of
telomerase has been implicated in cell immortalization and
tumorigenesis. Telomerase is thus a potentially attractive target for
cancer therapy.
We and others (Albanell et al, 1996; Bestilny et al, 1996; Holt
et al, 1996; Xu et al, 1996) have demonstrated that the suppression
of telomerase activity in promyelocytic leukaemic cells follows
terminal differentiation induced by various differentiating agents.
However, the mechanisms of telomerase inactivation during
differentiation of HL-60 cells remain unknown. Only lately is our
understanding of the regulation of telomerase activity starting to
emerge thanks to the identification of the human telomerase
subunits (Feng et al, 1995; Harrington et al, 1997; Kilian et al,
1997; Meyerson et al, 1997; Nakamura et al, 1997). Telomerase
subunits RNA template (hTR) and telomerase associated protein
(TP1) were found largely unchanged or even increased in differen-
tiated promyelocytic leukaemic cell lines (Meyerson et al, 1997;
Reichman et al, 1997). These results are in accordance with the
observation that hTR and TP1 are expressed both in normal and in
malignant human cells and that their expression levels do not
correlate with the biological activity of telomerase (Feng et al,
1995; Meyerson et al, 1997; Nakamura et al, 1997). Most
recently, the RNA encoding the human telomerase catalytic
component called telomerase reverse transcriptase (hTERT) has
been cloned (Kilian et al, 1997; Meyerson et al, 1997; Nakamura
et al, 1997). Accumulated data support the notion that the expres-
sion of hTERT is a rate-limiting step in the control of telomerase
activity. Telomerase activity can be reconstituted by the ectopic
expression of hTERT in human normal telomerase-negative
fibroblasts (Bodnar et al, 1998). A down-regulation of hTERT
expression has been observed in HL-60 cells induced to differen-
tiate by treatment with all-trans retinoic acid (ATRA) (Meyerson
et al, 1997).
The present work was undertaken to further evaluate alterations
in telomerase activity, as well as hTERT, hTR and TP1 expression
during terminal differentiation of HL-60 cells, and especially
address the regulatory mechanisms of hTERT expression in this
model.
MATERIALS AND METHODS
Chemicals and cell culture
ATRA, actinomycin D (ACD) and cycloheximide (CHX) were
purchased from Sigma (St Louis, MO, USA), dimethyl sulphoxide
(DMSO) from Merck (Darmstadt, Germany) and dihydroxy-
vitamin D3 (VD3) from Abbott Laboratories (North Chicago, IL,
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USA). HL-60 cells were grown in RPMI-1640 medium (Life
Technologies, Paisley, UK) supplemented with 10% fetal calf
serum (FCS), 100 U ml–1 penicillin and 2 mML -glutamine. For the
induction of differentiation, the cells at 0.25–0.5 ´ 106 per ml were
treated with 2 ´ 10–6 M ATRA, or 5 ´ 10–7 M VD3, or 1.25% v/v
DMSO and harvested at various time points. Viable cells always
exceeded 90% as determined by the trypan blue exclusion dye test.
For serum starvation, HL-60 cells were washed twice with
phosphate-buffered saline (PBS) and then incubated in the same
medium but without FCS.
Assays for differentiation
CD11b antigen expression was chosen as the specific marker for
HL-60 cell differentiation towards both granulocytes and mono-
cytes. CD11b antigen determination and the isolation of CD11b-
positive and -negative cells have been described in detail
elsewhere (Xu et al, 1996).
Telomerase activity assay
A commercial telomerase polymerase chain reaction (PCR)
enzyme-linked immunosorbent assay (ELISA) kit (Boehringer
Mannheim, Stockholm), based on telomeric repeat amplification
protocol (TRAP) introduced by Kim et al (1994), was used to
determine telomerase activity in control and differentiating agents-
treated HL-60 cells according to the manufacturer’s protocol
during 25 PCR cycles (Xu et al, 1998). Protein extraction and
measurement was performed as described previously (Xu et al,
1996).
RNA extraction and reverse transcription
Total cellular RNA was extracted by using the ULTRASPEC™– II
RNA kit (Biotecx Lab., Houston, TX, USA). To purify nuclear
RNA, cells were first suspended in ice-cold NP-40 containing lysis
buffer (10 mmol Tris, pH 7.4, 10 mmol sodium chloride, 3 mmol
magnesium chloride and 0.5% NP-40), centrifuged at 800 g for
5 min and washed three times with the same buffer. The isolated
nuclei were then subjected to RNA extraction with the above kit.
RNA yield and purity were determined spectrophotometrically at
260–280 nm (Perkin-Elmer, Lambda Bio) and the integrity of
RNA verified by electrophoretic size separation in 1% ethidium
bromide-stained agarose gels. cDNA was synthesized using
random primers (N6) (Pharmacia, Uppsala, Sweden) and MMLV
reverse transcriptase, as described earlier (Xu et al, 1998).
Quantitative determination of hTERT, hTR and TP1
expression by competitive RT-PCR
PCR primer sequences and conditions were described by
Nakamura et al (1997). The competitive templates of hTERT, hTR
and TP1 fragments, constructed by mimic PCR, were 21 bp longer
than their wild-type counterparts. cDNA corresponding to 50 ng of
RNA was co-amplified with appropriate competitors (5 ´ 103, 104
and 103 molecules for hTERT, hTR and TP1 respectively) in 25 ml
of reaction mixture. PCR was performed using 32, 31 and 31
cycles for hTERT, hTR and TP1 respectively. In addition, b2-
microglobulin (b2M) expression was used as a control for RNA
loading and RT efficiency and co-amplified with its competitors
(2.5 ´ 104 molecules) with the following RNA-specific primers
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Figure 1 Validation of quantitative detection of hTERT mRNA by using
competitive RT-PCR. (A) Serial dilutions of RNA derived from untreated
(upper) and ATRA-treated HL-60 cells (lower) for 8 h were coamplified with
the fixed number of competitors (5 ´ 103 molecules). The resulting PCR
products were resolved in 4% of Metaphor gels stained with ethidium
bromide and photographed. The images were analysed by densitometry. The
signal intensity ratio of hTERT mRNA to the competitor was plotted against
the amount of RNA present in each lane. (B) The fixed amounts of total RNA
(50 ng) derived from untreated (upper) and ATRA-treated HL60 cells (lower)
for 8 h were co-amplified with the different numbers of competitors and the
ratio of hTERT mRNA to the competitor was plotted against the number of
competitors present in each lane. C: Competitor1158 D Xu et al
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(5¢-primer: GAATTGCTATGTGTCTGGGT; 3¢-primer: CATCTT-
CAAACCTCCATGATG) during 25 cycles (94°C for 30 s, 60°C
for 30 s and 72°C for 60 s) (Xu et al, 1998). PCR products were
resolved in 4% Metaphor agarose gels stained with ethidium
bromide, visualized in UV light and photographed. Volumetric
integration of signal intensities was performed by using the NIH
image software (Version 1.58). The relative levels of hTERT, hTR
and TP1 mRNA were given by the ratio of the target to competitor
signal intensity and normalized to the ratio of b2M to its
competitor.
Determination of cell cycle distribution by flow
cytometry
By using the Cycle TEST™ PLUS DNA Reagent kit (Becton-
Dickinson, San José, CA, USA) DNA profile was determined in
untreated and treated HL-60 cells. Briefly, 1 ´ 106 cells were
treated with trypsin and RNAase, stained in propidium iodide
and evaluated by flow cytometry (Becton-Dickinson). The cell
percentage in G0/G1, S and G2/M phases was calculated by using
Mod Fit LT for Mac V2 software (Becton-Dickinson).
RESULTS AND DISCUSSION
Validation of quantitative RT-PCR for hTERT, hTR and
TP1 expression
As shown in Figure 1A, the signal ratio of the hTERT and co-
amplified competitor PCR products, with a less than 20% coeffi-
cient variation (CV), corresponded well to the dilution factor of
RNA derived from HL-60 cells. A linearity of hTERT assay was
also demonstrated at the fixed amount of RNA input with different
numbers of competitors (Figure 1B). Similar results were obtained
with hTR and TP1 quantification (data not shown).
Differential regulation of telomerase subunit
expression during differentiation of HL-60 cells
As reported previously, differentiating-agents DMSO, ATRA and
VD3 induce HL-60 cells to undergo terminal differentiation which
was accompanied by the suppression of telomerase activity (Holt
et al, 1996; Xu et al, 1996; Meryerson et al, 1997).
Since telomerase is a multicomponent reverse transcription
enzyme, the control of telomerase activity may operate at multiple
levels. So far, no studies have addressed the gene expression levels
of all three telomerase subunits during terminal differentiation
of HL-60 cells. Moreover, previous reports produced conflicting
results with regard to hTR expression in differentiated promyelo-
cytic leukaemic cells (Bestilny et al, 1996; Meyerson et al, 1997).
The extended evaluation of the gene expression of all three telom-
erase components, hTERT, hTR and TP1 was performed on HL-60
cells treated with differentiating agents. In the presence of DMSO
or ATRA, the level of hTERT mRNA declined rapidly; only less
than 10% of the control level remained after 24 h (Figure 2).
Clearly, the down-regulation of hTERT expression is an early
event in differentiated HL-60 cells. Compared to DMSO or
ATRA-treated cells, a relatively high level of hTERT still
remained in VD3-treated HL-60 cells after 120 h (data not shown).
The explanation for this discrepancy is that VD3 treatment induces
differentiation in 60–70% of HL-60 cells and that remaining undif-
ferentiated HL-60 cells constitutively express hTERT mRNA.
This was documented in Figure 3, showing that hTERT expression
remained at a high level in undifferentiated CD11b2 cells but was
hardly detectable in CD11b+ cells after the exposure of HL-60
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Figure 2 Telomerase activity and its subunits hTERT, hTR and TP1
expression in HL-60 cells treated with DMSO. (A) hTERT, hTR, TP1 and b2M
cDNA were co-amplified with their competitors, respectively, and PCR
products were resolved in 4% Metaphor gels stained with ethidium bromide.
C: Competitor. (B) The ethidium bromide-stained PCR products shown in
panel A were photographed and the images analysed by densitometry. The
intensity ratio of the target mRNA to the competitor normalized to the ratio of
b2M/Competitor in each lane was expressed as the percentage of that in
untreated HL-60 cells. Telomerase activity at each time point, determined by
using telomerase PCR–ELISA kit, was expressed as the percentage of that
in untreated HL-60 cells. Data shown is one representative of two separate
experiments
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Figure 3 hTERT expression in CD11b+ and CD11b2 HL-60 cells treated
with VD3. The cells were incubated with 5 ´ 10–7 mM of VD3 for 72 h and
CD11b+ and CD11b+ cells were separated by using Mini-MAX. Total cellular
RNA was extracted and subjected to competitive RT-PCR analysis for
hTERT expression. C: CompetitorDown-regulation of hTERT in differentiated HL-60 cells 1159
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cells to VD3 for 72 h. The data indicate that the down-regulation of
hTERT expression during the terminal differentiation of HL-60
cells is a differentiation-related event. Consistent with this, when
another myeloid leukaemic cell line, K562 cells, known not to be
terminally differentiated by treatment with ATRA, were incubated
with 2 mM of ATRA, there was no detectable change in hTERT
mRNA levels within 96 h (data not shown).
In contrast, up to 70% increase in TP1 mRNA was observed in
HL-60 cells incubated with all three differentiating agents (Figure
2). hTR expression levels of differentiated HL-60 cells remained
largely unchanged as compared to the control cells (Figure 2).
The observation that suppression of telomerase activity is
accompanied by down-regulation of hTERT mRNA, but not hTR
and TP1 expression in differentiated HL-60 cells supports the
notion that hTERT is the rate-limiting determinant of telomerase
activity. Down-regulation of hTERT expression in HL-60 cell
differentiation model may represent a general regulatory pathway
through which telomerase becomes inactivated during develop-
ment and differentiation of human somatic cells. Unlike hTERT,
the expression of hTR is loosely controlled and is up-regulated in
many human malignant and normal cell types with a correlation to
active proliferation status, but not telomerase activity (Greider,
1998). A recent investigation (Beattie et al, 1998) showed that the
coexpression of hTERT protein and hTR is capable of reconsti-
tuting enzyme activity of telomerase in vitro, suggesting that the
core enzyme complex may consist of only two components,
hTERT and hTR. Taken together, TP1 expression may be redun-
dant in terms of the regulation of telomerase activity.
Regulatory mechanisms of hTERT expression in
differentiated HL-60 cells
Since hTERT expression is the determinant for the control of
telomerase activity and it has been shown that the induction of
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Figure 4 hTERT expression and cell cycle distribution in ATRA-treated and
serum-deprived HL-60 cells. Exponentially growing cells were treated with
2 mM ATRA or serum-starved for 24 h and harvested for RNA extraction and
cell cycle analysis. (A) Expression of hTERT mRNA in ATRA-treated and
serum-deprived HL60 cells. C: Competitor. (B) The ethidium bromide-stained
PCR products shown in panel A were photographed and the images were
analysed by densitometry. The signal intensity ratio of hTERT mRNA to the
competitor normalized to the ratio of b2M/Competitor in each lane was
expressed as the percentage of that in untreated HL-60 cells. (C) DNA
content flow cytometric profiles in ATRA-treated and serum-deprived HL-60
cells for 24 h. The experiments were performed twice with similar results
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Figure 5 The transcription rate of hTERT gene in ATRA-treated HL60 cells
determined by using competitive RT-PCR. (A) Nuclear RNA was extracted
and subjected to RT-PCR with hTERT competitors. b2M was coamplified with
its competitors. C: Competitor. (B) The transcription rate of hTERT gene was
expressed as the percentage of that in untreated HL-60 cells according to the
signal intensity ratio of hTERT/competitor. The analysis was performed twice
with similar results1160 D Xu et al
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hTERT expression is required for telomerase activation during
cellular immortalization and tumour progression, elucidation of
the regulatory mechanisms of hTERT expression will certainly
contribute to a better understanding of telomerase activity control
at the molecular level.
Some recent observations have suggested that telomerase
activity is growth-regulated, high in the actively cycling culture
and low in the quiescent cells (Greider, 1998). As differentiated
HL-60 cells eventually exit out of cell cycle, we thus ask whether
the down-regulation of telomerase activity and hTERT expression
is simply related to the cellular proliferation status. As shown in
Figure 4, ATRA-treated HL-60 cells exhibited a rapid decline in
hTERT expression and a slight cell cycle arrest within 24 h. On the
contrary, 24 h of serum starvation of HL-60 cells had a similar
effect on the cell cycle arrest as ATRA-treatment, but there was no
clear change in hTERT mRNA level during this period (Figure 4).
A significant down-regulation of hTERT expression in serum-
deprived HL-60 cells was observed after 48 h of incubation
without FCS (data not shown). It is evident from the present data
that the differentiation-triggered down-regulation of hTERT
expression in HL-60 cells is a more active process, not simply a
consequence of cell cycle arrest.
To determine whether hTERT transcripts are modulated in
differentiated HL-60 cells due to alteration in transcriptional
activity in nuclei, nuclear RNA was isolated and the levels of
nascent hTERT mRNA was measured by competitive RT-PCR, a
method which gives identical results as nuclei run-off test, a
classical assay for transcription rate of gene expression (Herzog
et al, 1993). As seen in Figure 5, the transcription rate of hTERT
declined rapidly in ATRA-treated HL-60 cells and only a very low
level of activity was recorded after 24 h. b2M as an internal control
for loading amounts of nuclear RNA was analysed in parallel on
nuclear RNA.
We then asked whether post-transcriptional regulation affects
hTERT mRNA levels. To compare the stability of hTERT tran-
scripts between untreated and ATRA-treated HL-60 cells, analysis
of the hTERT mRNA half-life was performed by incubating
HL-60 cells with ACD at 10 mg ml–1 and purifying RNA at the
indicated time points. New RNA synthesis was blocked by ACD,
which was demonstrated by almost no 3H-thymidine incorporated
into HL-60 cells in the presence of 10 mg ml–1 of ACD. HL-60
cells had been exposed to ATRA for 3 h prior to the addition of
ACD. This caused a lower basic expression level of hTERT
mRNA at time 0 compared to the control sample. The half-life of
hTERT mRNA in the control HL-60 cells ranged between 2.6 and
3.8 h (median 3 h) in three experiments, whereas that of ATRA-
treated HL-60 cells was 2.4–3.2 (median 2.6 h) (Figure 6). The
difference in the stability of hTERT mRNA was not significant,
but it is likely that the slightly shortened half-life of hTERT tran-
scripts in differentiated HL-60 cells partially results in decline
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in the levels of hTERT mRNA. The short half-life of hTERT
transcripts provides the explanation for the rapid reduction of
hTERT mRNA and delay in the decline of telomerase activity with
a longer half-life seen in differentiated HL-60 cells.
Finally, we wanted to address the question whether ongoing
protein synthesis was required for differentiation-triggered down-
regulation of hTERT expression. New protein synthesis was fully
blocked in the presence of 100 mg ml–1 of CHX, an inhibitor
of protein synthesis (Matikainen et al, 1996). HL-60 cells were
incubated with CHX at 100 mg ml–1 for 20 min first, and thereafter
ATRA or DMSO was added to the culture for up to 4 h.
Quantitative RT-PCR analysis showed that the downregulation of
hTERT transcripts induced by ATRA was blocked in the presence
of CHX (Figure 7). A similar result was obtained in DMSO plus
CHX-treated HL-60 cells (data not shown). These observations
suggest that new protein(s) are involved in the hTERT mRNA
modulation process.
In summary, the suppression of telomerase activity is preceded
by a down-regulation of hTERT mRNA but unrelated to the
expression of hTR and TP1 during differentiation of HL-60 cells.
The onset of reduction of hTERT expression during cellular differ-
entiation is at least in part independent of cell proliferation status.
We further demonstrate that the down-regulation of hTERT
mRNA in differentiated HL-60 cells is achieved through inhibition
of its transcription. In these regulatory processes, active protein
synthesis is required and the newly synthesized protein(s) partici-
pate in either transcription inhibition or controlling of the steady-
state level of hTERT mRNA. These findings provide new insights
into regulatory control of telomerase activity at the molecular level
and may be useful for future development of anti-telomerase
strategy against human malignancies.
ACKNOWLEDGEMENTS
This work was supported by the Swedish Cancer Society, the
Cancer Society in Stockholm, Karolinska Institute Funds and the
King Gustaf Vth Jubilee Fund. PP is a research fellow of the
Swedish Medical Research Council.
REFERENCES
Albanell J, Han W, Mellado B, Gunawardane R, Scher H and Dmitrovsky E (1996)
Telomerase activity is repressed during differentiation of maturation-sensitive
but not resistant human tumor cell lines. Cancer Res 56: 1503–1508
Beattie TL, Zhou W, Robinson MO and Harrington L (1998) Reconstitution of
telomerase activity in vitro. Curr Biol 8: 177–180
Bestilny L, Brown C, Miura Y, Robertson L and Riabowol K (1996) Selective
inhibition of telomerase activity during terminal differentiation of immortal cell
lines. Cancer Res 56: 3796–3802
Bodnar A, Ouellette M, Frolkis M, Holt S, Chiu C, Morin G, Harley C, Shay J,
Lichtsteiner S and Wright W (1998) Extension of life-span by introduction of
telomerase into normal human cells. Science 279: 349–352
Feng L, Funk W, Wang S-S, Weinrich S, Avillion A, Chiu C, Adams R, Chang E,
Allsopp R, Yu J, Le S, West M, Harley C, Andrews W, Greider C and
Villeponteau B (1995) The RNA component of human telomerase. Science
269: 1236–1241
Greider CW (1998) Telomerase activity, cell proliferation, and cancer. Proc Natl
Acad Sci USA 95: 90–92
Harley CB, Kim NW, Prowse KR, Weinreich SL, Hirsch KS, West MD, Bacchetti S,
Hirte HW, Counter CM, Greider CW, Piatyszek MA, Weight WE and Shay JW
(1994) Telomerase, cell immortality, and cancer. Cold Spring Harbor Symp
Quant Biol 59: 307–315
Harrington L, Mcphail T, Mar V, Zhou W, Oulton R, Bass M, Arruda I and Robinson
M (1997) A mammalian telomerase-associated protein. Science 275: 973–977
Herzog C, Tsokos M, Bates S and Fojo A (1993) Increased mdr-1/p-glycoprotein
expression after treatment of human colon carcinoma cells with p-glycoprotein
antagonists. J Biol Chem 268: 2946–2952
Holt SE, Wright WE and Shay JW (1996) Regulation of telomerase activity in
immortal cell lines. Mol Cell Biol 16: 2932–2939
Kilian A, Bowtell DDL, Abud HE, Hime GR, Venter DJ, Keese PK, Duncan EL,
Reddel RR and Jefferson RA (1997) Isolation of a candidate human telomerase
catalytic subunit gene, which reveals complex splicing patterns in different cell
types. Hum Mol Genet 12: 2011–2019
Kim N, Ma MP, Prowse K, Harley C, West M, Ho P, Coviello G, Wright W,
Weinrich S and Shay J (1994) Specific association of human telomerase
activity with immortal cells and cancer. Science 266: 2011–2015
Matikainen S, Ronni T, Hurme M, Pine R and Julkunen (1996) Retinoic acid
activates interferon regulatory factor-1 gene expression in myeloid cells. Blood
88: 114–123
Meyerson M, Counter C, Eaton E, Ellisen L, Steiner P, Caddle S, Ziaugra L,
Beijersbergen R, Davidoff M, Liu Q, Bacchetti S, Haber D and Weinberg R
(1997) hEST2, the putative human telomerase catalytic subunit gene, is up-
regulated in tumor cells and during immortalization. Cell 90: 785–795
Nakamura T, Morin G, Chapman K, Weinrich S, Andrews W, Lingner J, Harley C
and Cech T (1997) Telomerase catalytic subunit homologs from fission yeast
and human. Science 277: 955–959
Reichman T, Albanell J, Wang X, Moore M and Studzinski G (1997)
Downregulation of telomerase activity in HL60 cells by differentiating agents
is accompanied by increased expression of telomerase-associated protein. 
J Cell Biochem 67: 13–23
Xu D, Gruber A, Peterson C and Pisa P (1996) Suppression of telomerase activity in
HL60 cells after treatment with differentiating agents. Leukemia 10:
1354–1357
Xu D, Gruber A, Peterson C and Pisa P (1998) Telomerase activity and the
expression of telomerase components in acute myelogenous leukaemia. Br J
Haematol 102: 1365–1373.